Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth

Article  (Published Version)


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/102834/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth

Alessio Lepore,1* Pui Man Choy,2* Nathan C.W. Lee,1 Maria Annunziata Carella,3 Rosy Favicchio,4 Marco A. Briones-Orta,2,5 Shannon S. Glaser,6 Gianfranco Alpini6,7 Clive D’Santos,8 Reuben M. Tooze,1 Mihaela Lorger,1 Wing–Kin Syn,2,9-11 Athanasios Papakyriakou10,12 Georgios Giamas13, Concetta Bubici13,3** and Salvatore Papa13,1,2**

BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive type of liver cancer in urgent need of treatment options. Aberrant activation of the c-Jun N-terminal kinase (JNK) pathway is a key feature in ICC and an attractive candidate target for its treatment. However, the mechanisms by which constitutive JNK activation promotes ICC growth, and therefore the key downstream effectors of this pathway, remain unknown for their applicability as therapeutic targets. Our aim was to obtain a better mechanistic understanding of the role of JNK signaling in ICC that could open up therapeutic opportunities.

APPROACH AND RESULTS: Using loss-of-function and gain-of-function studies in vitro and in vivo, we show that activation of the JNK pathway promotes ICC cell proliferation by affecting the protein stability of peptidyl-prolyl cis-trans isomerase NIMA-interactive 1 (PIN1), a key driver of tumorigenesis. PIN1 is highly expressed in ICC primary tumors, and its expression positively correlates with active JNK. Mechanistically, the JNK kinases directly bind to and phosphorylate PIN1 at Ser115, and this phosphorylation prevents PIN1 mono-ubiquitination at Lys117 and its proteasomal degradation. Moreover, pharmacological inhibition of PIN1 through all-trans retinoic acid, a Food and Drug Administration–approved drug, impairs the growth of both cultured and xenografted ICC cells.

CONCLUSIONS: Our findings implicate the JNK-PIN1 regulatory axis as a functionally important determinant for ICC growth, and provide a rationale for therapeutic targeting of JNK activation through PIN1 inhibition. (HEPATOLOGY 2021;74:2561-2579).

Intrahepatic cholangiocarcinoma (ICC) is a tumor of the bile ducts within the liver that arises primarily from an uncontrolled proliferation of transformed cholangiocytes. With a global increasing incidence and mortality rates, ICC represents the second-most-frequent primary liver tumor after HCC.1-3 Currently, there are no curative chemotherapies for ICC, and efforts to develop molecular-targeted therapies have been limited due to the lack of a detailed understanding of the molecular mechanisms underlying the disease.2 ICC usually develops in the context of both chronic inflammation of the biliary tract and liver injury that foster the accumulation of genetic mutations.
in proto-oncogenes and tumor suppressors, such as KRAS and p53, which in turn lead to the constitutive activation of signaling pathways involved in cell proliferation.\(^4-7\) One of the major signaling pathways that are activated by mutant KRAS in ICC models is the c-Jun N-terminal kinase (JNK) signaling,\(^8\) a member of the mitogen-activated protein kinase (MAPK) family.\(^9-11\) Activation of JNK signaling facilitates the development of ICC by promoting the hyperproliferation of transformed bile duct cells.\(^8\) Although the pharmacologic inhibition of the JNK kinase activity impairs the development of ICC in several mouse models of liver injury,\(^8\) active JNK is a challenging protein to target, due to its physiological and cell type-specific functions in the liver.\(^12-15\) Therefore, we sought to obtain a better understanding of the mechanisms by which active JNK signaling promotes ICC, because the identification of the major downstream effectors of the JNK/MAPK pathway could lead to the development of much-needed molecular-targeted therapeutics.

A key downstream effector of the oncogenic KRAS signal is PIN1, an evolutionarily conserved peptidyl-prolyl cis-trans isomerase (PPIase). PIN1 catalyzes the cis-trans isomerization of peptidyl-prolyl bonds in phosphorylated Ser/Thr-Pro motifs of the target proteins.\(^16-21\) Through its PPIase activity, PIN1 affects the function of a large and diverse array of phosphorylated target proteins, including oncoproteins and tumor suppressors.\(^18-24\) PIN1 is frequently highly expressed in human cancers, and its expression correlates with poor patient prognosis.\(^20,24\) For instance, PIN1 is overexpressed in invasive ductal carcinoma breast cancer, and cooperates with activated JNK and oncogenic RAS in promoting deregulated cell proliferation by increasing the expression of the cell cycle regulator cyclin D1.\(^16,17,24\) PIN1 also cooperates with oncogenic KRAS in driving cellular transformation in pancreatic ductal adenocarcinoma (PDAC) and is required for PDAC cell viability.\(^21\) Given that ICC is driven by mutant KRAS and active JNK,\(^4,5,8\) and that a proportion of invasive ductal carcinoma breast cancer and PDAC share an inflammatory origin with ICC,\(^8,25,26\) an interesting question is whether PIN1 plays a role in ICC. However, because genetic and/or genomic studies to date have rarely found mutations and amplifications of the PIN1 gene,\(^24\) the molecular mechanisms underlying
PIN1 overexpression need to be understood at the cell signaling level.

Here we demonstrate that the constitutive activation of JNK leads to elevated levels of PIN1 expression, thus promoting ICC cell proliferation. We show that JNK proteins directly interact with and phosphorylate PIN1 at Ser115. The phosphorylation of PIN1 at this specific residue directly causes the increase in intracellular PIN1 levels by preventing its mono-ubiquitination at Lys117, and, consequently, inhibiting its proteasomal degradation. We also show the potential application of PIN1 inhibition using all-trans retinoic acid (ATRA) for ICC therapy.

Materials and Methods

TISSUE MICROARRAYS AND IMMUNOHISTOCHEMISTRY

Formalin fixed paraffin-embedded human ICC used in tissue microarrays (TMAs) were purchased from Pantomics (tissue block LVC1261), consisting of 42 cases, 126 cores, and one normal adjacent nontumor liver tissue core paired with two tumor tissue cores from each patient. Immunohistochemistry staining of sequential sections was carried out using a two-step protocol. After antigen retrieval, each TMA slide, consisting of serial tissue cuts, was incubated with validated anti-human PIN1 antibody (1:50; H123; Santa Cruz Biotechnology, Inc., Dallas, TX) and anti-human phospho(p)-JNK (1:50; 9251; Cell Signaling Technology). The quantification of PIN1 and phosphorylated JNK (p-JNK) staining was evaluated by randomly choosing five non-overlapping fields at ×40 for each core and quantified by counting the number of PIN1(+) or p-JNK(+) biliary epithelial cells/field and dividing by the total number of biliary epithelial cells per field.

XENOGRaFT TUMOR MODELS

For xenograft experiments, $3 \times 10^6$ CCLP1 parental or nonspecific short hairpin RNA (shNS)–expressing, JNK1/2 short hairpin RNA (shJNK1/2)–expressing, PIN1 short hairpin RNA (shPIN1)–expressing cells were injected subcutaneously into dorsal regions of 8-week-old female NOD/SCID (strain 394, Charles River) immunodeficient mice. Body weight and tumor sizes were recorded over time by a caliper, and tumor volumes were calculated using the formula $L \times W^2 \times 0.52$, where $L$ and $W$ represent the length and width, respectively. For ATRA treatment, 2 weeks later mice injected with CCLP1 parental cells were randomly selected to receive ATRA or control (placebo) treatment using time-release (over 21 days) drug pellets. For implantation, placebo or 10 mg of ATRA-releasing pellets (Innovative Research of America, Sarasota, FL) were implanted subcutaneously in the flank of tumor-bearing NOD/SCID mice. At sacrifice, the tumors were recovered, photographed, and the wet weight of each tumor was recorded. Each tumor was snap-frozen for further analysis. All experiments were carried out with approval from the UK Home Office Authority (PPL70/8448; PEA0105B1).

RESULTS

JNK ACTIVITY CORRELATES WITH PIN1 EXPRESSION AND REGULATES ITS PROTEIN LEVELS IN CHOLANGIOCARCINOMA

As RAS mutations are a key event in cholangiocarcinogenesis, and both PIN1 and JNK activation were previously identified as downstream targets of oncogenic RAS we investigated a possible relationship between PIN1 and JNK signaling in ICC. First, we analyzed the expression levels of PIN1 and phospho-JNK (p-JNK; a proxy for active JNK) in consecutive sections of ICC TMA by immunohistochemistry using antibodies of anti-PIN1 or anti-p-JNK, which detect phosphorylated JNK1 and JNK2, two major JNK kinases. We found that,
compared with adjacent nontumor biliary cells, an increased percentage of ICC epithelial cells expressed PIN1 (18.64 vs. 41.25) and p-JNK (6.19 vs. 20.13), the levels of which positively correlated each other (Fig. 1A,B and Supporting Fig. S1A). Using western blot (WB), we then evaluated the expression of PIN1 and p-JNK in ICC-derived cell lines (CCLP1, HuCCT1, and SG231) and observed higher levels of both PIN1 and p-JNK in all three ICC cell lines when compared with primary normal intrahepatic biliary epithelial cells (Fig. 1C). Moreover, analysis of JNK activation by in vitro kinase assays showed considerable increase of the kinase activities of JNK1 and JNK2 in ICC cells compared with nontumoral immortalized human H69 cholangiocytes, whereas the overall PIN1 protein levels were similar in ICC and H69 cells (Fig. 1D), suggesting a potential JNK-PIN1 pathway that is specific to ICC.

Next, we knocked down the expression of JNK proteins in ICC cells using short hairpin RNA (shRNA) lentiviruses targeting both JNK1 and JNK2 (shJNK1/2), and analyzed PIN1 expression levels. As controls, we used lentiviruses expressing shNS. Efficient knockdown was verified by WB (Fig. 1E). Knockdown of JNK1/2 resulted in a marked reduction of PIN1 protein levels (Fig. 1E) with no significant effect on PIN1 mRNA levels (Fig. 1F), suggesting that JNK proteins regulate PIN1 at the post-transcriptional level. Similar results were obtained in ICC cells depleted of either JNK1 or JNK2 (Supporting Fig. S1B,C). Intriguingly, reduced PIN1 protein levels were not observed in JNK1/2-silenced H69 cells (Fig. 1E). This indicates that the effect of JNK on PIN1 expression is specific to ICC cells, in which JNK is constitutively active (see Fig. 1C,D). Indeed, a decrease in PIN1 protein levels was observed when we treated ICC cells with the JNK inhibitor SP600125 (Fig. 1G), which specifically blocked phosphorylation/activity of JNK1/2 without affecting phosphorylation/activity levels of other related MAPK proteins (ERK and p38). Remarkably, no significant differences in phosphorylation/activity levels of JNK were observed when we knocked down PIN1 expression in ICC cells using shPIN1 (Supporting Fig. S1D), which is consistent with the hypothesis that JNK proteins function upstream of PIN1. Moreover, WB of lysates from CCLP1 cells infected with a lentivirus expressing a constitutively active form of JNK1 (JNK1CA) revealed that expression levels of endogenous PIN1 were increased compared with control cells (Fig. 1H), suggesting a role for JNK activity in up-regulating PIN1 protein levels.

**PIN1 FUNCTIONALLY MIMICS JNK ACTIVATION IN CHOLANGIOCARCINOMA CELLS**

Because JNK activity positively regulates PIN1 protein levels (Fig. 1E,G,H and Supporting Fig. S1B) and its inhibition impairs ICC cell proliferation, we investigated whether this was the case for PIN1. Compared with control silencing, knockdown of PIN1 significantly attenuated the growth rate and reduced the colony-forming ability of ICC cells to the same extent as JNK1/2 knockdown (Fig. 2A-D and Supporting Fig. S2A-C). The growth defect of PIN1-depleted cells was specific to the lack of PIN1, as reconstituted expression of shRNA-resistant wild-type (WT) PIN1 (rPIN1 WT) in these cells reversed this defect (Supporting Fig. S2D). The effects of knockdown of either PIN1 or JNK1/2 were also confirmed by decreased cell mass accumulation (Supporting Fig. S2E-G). Notably, depletion of either PIN1 or JNK1/2 had no effect on the growth rate or cell mass accumulation of H69 cells (Fig. 2A,B and Supporting Fig. S2E-G). Furthermore, we observed a significant reduction of bromodeoxyuridine incorporation in PIN1 knockdown cells with a concomitant decrease in the levels of various cell-cycle regulators (Supporting Fig. S2H,I), indicating that PIN1 depletion attenuates ICC cell proliferation. These reductions occurred in the absence of any significant induction of apoptosis, as determined by measurement of the percentage of the sub-G1 population and caspases cleavage (Supporting Fig. S2J,K). Similar results were observed in JNK1/2 knockdown cells (Supporting Fig. S2L-O). Moreover, when subcutaneously injected into NOD/SCID immunodeficient mice, CCLP1 cells with PIN1 or JNK1/2 knockdown gave rise to smaller tumors compared with those of control silencing, as revealed by measuring tumor mass and weight (Fig. 2E-H). In contrast to the effects induced by PIN1 depletion, ectopic expression of PIN1 led to a significant increase in growth rate and colony formation of ICC cells (Fig. 2I,J). These effects faithfully mimicked those of JNK1CA overexpression (Fig. 2K,L). Together, these results indicate
- **A**:adjacent nontumour, ICC
- **B**:pin-JNK expression
- **C**:primary cholangiocytes
- **D**:immortalised cholangiocytes
- **E**:shNS, shJNK1/2
- **F**:shNS, shJNK1/2
- **G**:DMSO, SP600125
FIG. 1. Active JNK positively correlates and regulates PIN1 levels in human ICC. (A) Immunohistochemistry on serial sections of 42 paired nontumor adjacent (left panels) and ICC tissue (right panels) stained for p-JNK and PIN1. Dot plots graphs indicate the percentage of biliary cells positively stained for p-JNK and PIN1 in nontumor and ICC tissue (n = 42 per group). Data shown in the ICC group are the average results of duplicate samples. Data are presented as mean ± SEM; circles represent individual data points. P value was determined by Wilcoxon matched-pairs signed-rank test. Photomicrographs: scale bars = 300 μm (top) and 100 μm (bottom); magnification = ×10 (top) and ×40 (bottom). (B) Scatterplots showing the positive correlation between p-JNK and PIN1 protein expression in nontumor adjacent and ICC tissue. Pearson’s coefficient tests were performed to assess statistical significance. (C) WB analyses detecting p-JNK and PIN1 in lysates of normal HIBEpiC and ICC-derived cell lines (CCLP1, HuCCT1, and SG231). Actin and total JNK were used as loading control. Arrows denote the expression levels of spliced variants p46 and p54 of JNK1 and JNK2. (D) WB and kinase assay analyses detecting PIN1 expression and JNK1 and JNK2 kinase activities in indicated ICC cell lines and nontumoral human immortalized cholangiocytes (H69). (24) Actin and total JNK1 and JNK2 protein levels were used as loading control. (E) WBs showing a reduction of PIN1 levels in indicated ICC cell lines but not in H69 cells infected with lentiviruses expressing shJNK1/2 compared with control shNS. WBs (bottom panels) showing the JNK1/2 knockdown efficiency. The bar graphs represent the quantification of the relative PIN1 levels normalized to actin. (F) Bottom: Gel of PIN1 mRNA levels, as detected by real-time PCR, in CCLP1-expressing shJNK1/2 and control shNS. Top: Graph showing quantification of the data presented as mean ± SEM; circles represent individual data points. GAPDH, control. P value was determined by the Student t test. (G) WB analyses showing a reduction of PIN1 levels in indicated ICC cell lines treated with 10 μM JNK inhibitor SP600125 compared with vehicle (DMSO)–treated control. Detection of p-JNK, p-c-Jun, p-p38, and p-ERK is shown to demonstrate effective inhibition of specific JNK kinase activity. Tubulin, control. The bar graphs represent the quantification of the relative PIN1 levels normalized to tubulin. (H) WB analyses showing increased expression of PIN1 in CCLP1 cells infected with lentiviruses expressing FLAG-tagged constitutive active JNK1 (FLAG-JNK1CA) compared with EV. Actin, control. The bar graphs represent the quantification of the relative PIN1 levels normalized to actin. Results are representative of at least three independent experiments. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HIBEpiC, human primary cholangiocytes; K.A., kinase assay; p-ERK, phosphorylated extracellular signal-regulated kinase.

that PIN1 promotes ICC cell proliferation both in vitro and in vivo to a similar degree as JNK activation and suggest that JNK inhibition may impair ICC cell proliferation by lowering PIN1 levels.

**JNK INHIBITION DECREASES PIN1 LEVELS BY PROMOTING ITS MONOUBIQUITIN-PROTEASOME DEGRADATION**

The observation that JNK1/2 knockdown results in a decrease in PIN1 protein levels without affecting the levels of its mRNA (Fig. 1E,F and Supporting Fig. S1B,C) led us to examine whether JNK1/2 regulated PIN1 protein stability. For this purpose, we evaluated the half-life of PIN1 by performing pulse-chase assays in the presence of cycloheximide (CHX), which blocks protein synthesis. Depletion of JNK1/2 or chemical inhibition of JNK activity resulted in a decrease in the half-life of endogenous PIN1 in CCLP1 cells (Fig. 3A,B). Conversely, co-expression of JNK1CA but not a catalytically nonactive JNK1 protein resulted in an increase of the half-life of PIN1 in HEK293T cells (Supporting Fig. S3A,B). These findings indicate that active JNK1/2 up-regulate PIN1 levels by enhancing its protein stability.

As PIN1 has been reported to be degraded through the ubiquitin-proteasome system, (34-36) we examined whether JNK proteins elicit their effects on PIN1 stability through inactivation of the ubiquitin-proteasome system. (37) Treatment of JNK1/2-depleted ICC cells with the proteasome inhibitor MG132 was sufficient to completely revert the decrease in PIN1 protein levels in these cells (Fig. 3C), indicating that proteasome mediates the effects of JNK1/2 depletion on PIN1 levels. Similar results were obtained when we added MG132 to ICC cells pretreated with SP600125 to inhibit JNK activity (Fig. 3D). We then asked whether JNK could affect PIN1 ubiquitination, a key post-translational modification required for proteasomal degradation. FLAG-tagged PIN1 and His-tagged ubiquitin were co-expressed in HEK293T cells with or without HA-tagged JNK1CA, and the ubiquitination status of PIN1 was assessed by combined Ni-NTA pull-down (PD) and WB analyses. Expression of JNK1CA prevented the appearance of a single band corresponding in molecular weight to the mono-ubiquitinated form of PIN1 (Supporting Fig. S3C). Such an effect was also confirmed by co-immunoprecipitation (IP) analyses (Supporting Fig. S3D). Similar results were obtained when a mutant form of ubiquitin (UbK0), which allows only mono-ubiquitination due to the lack of lysine residues, (38) was used instead of WT ubiquitin (Supporting Fig. S3E). This confirms that PIN1 is subject to mono-ubiquitination, which is inhibited by
FIG. 2. JNK activity and PIN1 expression are similarly required for ICC cell growth both in vitro and in vivo. (A,B) Growth curves of CCLP1 (n = 6), HuCCT1 (n = 6), SG231 (n = 3), and nontumoral H69 cholangiocytes (n = 3) stably expressing PIN1, JNK1/2, or shNS. Data are shown as mean ± SEM and are representative of three independent cultures. (C,D) Anchorage-independent colony formation of CCLP1 and SG231 cells stably expressing shPIN1, shJNK1/2, or shNS. Representative images show overall view of colony growth after 3 weeks. Data shown are mean ± SEM of three independent cultures, and circles represent individual data points. P values were calculated by Student’s t test. (E) WBs showing PIN1 and JNK1/2 protein levels in lysates from CCLP1 cells stably expressing shNS, shJNK1/2, or shPIN1 used in xenograft experiments (injected cells). Tubulin and total JNK levels were analyzed with appropriate antibodies as controls. The bar graphs represent the quantification of the relative PIN1 levels normalized to tubulin. (F) Curves of tumor volume plotted over time following inoculation of CCLP1 cells described in (E). P values were calculated using the two-way ANOVA test. (G) Shown are sizes of tumors developed in mice 24 days following inoculation with CCLP1 cells as described in (E). (H) Tumor weight of explanted tumors at day 24 following post-inoculation. P values were calculated from one-way ordinary ANOVA test adjusted with Tukey’s multiple comparison tests. (I,K) Growth curves and anchorage-independent colony formation of CCLP1 ectopically expressing either FLAG-tagged PIN1 (n = 3) (I) or FLAG-JNK1CA (n = 3) (K) compared with EV (n = 3). Shown are representative light microscopy images of cultured cells (days 7 or 8 after complementary DNA expression) and overall view of colony growth after 3 weeks. Data shown are mean ± SEM of three independent cultures; circles represent individual data points. P values were calculated by Student’s t test. (J,L) WBs showing the ectopic or endogenous (endog.) levels of PIN1 and p-JNK in CCLP1 stably expressing FLAG-PIN1 (J) or FLAG-JNK1CA (L).

JNK1CA expression. Such inhibition was not observed when we co-expressed the catalytically nonactive JNK1 protein (Supporting Fig. S3F), suggesting that JNK kinase activity is required for preventing PIN1 mono-ubiquitination. Importantly, the inhibitory effect of JNK on PIN1 mono-ubiquitination was confirmed in ICC cells, as accumulation of endogenous mono-ubiquitinated PIN1 was observed in JNK1/2-depleted CCLP1 cells (Fig. 3E). Thus, the constitutive activation of JNK in ICC cells leads to high levels of PIN1 by preventing its mono-ubiquitination and degradation.

ACTIVE JNK PROTEINS INTERACT WITH AND PHOSPHORYLATE PIN1 AT Ser115

To gain insight into the mechanism by which JNK proteins stabilize PIN1, we co-expressed HA-tagged PIN1 in HEK293T cells with FLAG-tagged JNK1CA, FLAG-tagged JNK2CA or empty vector, and investigated protein associations by combined IP and WB analyses. Both FLAG-tagged JNK1CA and FLAG-tagged JNK2CA specifically bound to HA-PIN1 (Supporting Fig. S4A). Furthermore, in vitro kinase assays revealed that both active JNK1 and JNK2 efficiently phosphorylated recombinant glutathione S-transferase (GST)-fused PIN1, but not GST alone (Fig. 4A). As JNK1 and JNK2 shared common function with respect to their interaction with PIN1 and its phosphorylation, we focused our attention on JNK1 in further analyses. First, the interaction between PIN1 and active JNK1 was confirmed at the endogenous levels. Anti-active JNK1 antibodies (29,30) co-immunoprecipitated PIN1 from parental cells, but not from ICC cells depleted of PIN1 (WB:PIN1; Fig. 4B). JNK1 was immunoprecipitated at comparable levels in both parental cells and PIN1-depleted cells and was not co-precipitated by isotype-matched control antibodies (WB:JNK1; Fig. 4B). We then verified that PIN1 was phosphorylated by JNK1 in in vivo cells. PIN1 co-expressed with JNK1CA, but not with the catalytically nonactive JNK1 protein, was highly phosphorylated in HEK293T cells, as shown by a marked band shift of PIN1 on Phos-tag polyacrylamide gel electrophoresis (39). This shifted band disappeared when cell lysates were treated with the calf intestinal alkaline phosphatase (CIP) (Supporting Fig. S4B), confirming that the shifted band of PIN1 was a consequence of phosphorylation by active JNK1. Importantly, phosphorylation of endogenous PIN1 by JNK was confirmed in ICC cells, as the PIN1-shifted band disappeared in JNK1/2-depleted or SP600125-treated CCLP1 cells on Phos-tag immunoblots (Fig. 4C), indicating that PIN1 is indeed phosphorylated by JNK proteins in ICC cells.

To test whether JNK could directly phosphorylate PIN1, we performed in vitro kinase assays and found that recombinant active JNK1 efficiently phosphorylated purified His-PIN1 (Fig. 4D). Accordingly, in vitro pull-down analyses revealed direct interaction between active JNK1 and PIN1 (Fig. 4E). Altogether, these data indicate that PIN1 is a direct substrate of JNK1 kinase. In support of this notion, a single phosphorylation site (Ser115) was detected in PIN1 by mass spectrometry (Supporting Fig. S4C-F).
Sequence alignment analysis of PIN1 revealed that Ser115 is conserved among different species and located within the consensus phosphorylation motif for JNKs (115SA116) (40) (Supporting Fig. S4G). To confirm Ser115 as the specific JNK1 phosphorylation site on PIN1, a non-phosphorylatable alanine PIN1 mutant (S115A) was generated and used as a substrate for JNK1 in kinase assays. As controls, we individually mutated Ser114, a nearby JNK consensus phosphorylation site (114SS115), and Ser138, a residue known to be phosphorylated by the JNK-related kinase mixed-lineage kinase 3, into alanines (S114A and S138A). PIN1-S115A mutant, but not WT PIN1, PIN1-S114A or PIN1-S138A mutant, was resistant to phosphorylation by JNK1 in vitro (Fig. 4F). This result was confirmed in ICC cells expressing endogenous active JNK and in HEK293T cells expressing exogenous constitutively active JNK1 by Phos-tag immunoblots (Fig. 4G and Supporting Fig. S4H). Taken together, these results indicate that JNK1 directly phosphorylates PIN1 at Ser115 both in vitro and in vivo cells.
PHOSPHORYLATION OF PIN1 AT Ser115 PREVENTS ITS MONO-UBIQUITINATION AND DEGRADATION

To directly test the role of Ser115 phosphorylation in the control of PIN1 protein stability, we generated CCLP1 cells stably expressing FLAG-PIN1-WT, FLAG-PIN1-S114A, FLAG-PIN1-S115A, or FLAG-PIN1-S138A mutant and assessed the half-life of PIN1 mutant proteins in these cells, which have endogenous active JNK (Fig. 1C,D). Endogenous active JNK failed to prolong the half-life of the PIN1-S115A mutant, but not of PIN1-WT, PIN1-S114A, or PIN1-S138A mutant (Fig. 5A), implying that phosphorylation of PIN1 at Ser115 is required for PIN1 protein stability. Accordingly, PIN1-S115A mutant was heavily mono-ubiquitinated in CCLP1 cells, whereas WT PIN1 was resistant to mono-ubiquitination (Fig. 5B), indicating
that PIN1-S115A mutant is targeted for degradation. Similar results were observed in HEK293T cells ectopically expressing JNK1CA (Supporting Figs. S5A,B and S3C). Collectively, these data indicate that JNK-mediated PIN1 phosphorylation at Ser115 is essential for PIN1 protein stability. We next sought to identify the lysine residue on PIN1, which is targeted for mono-ubiquitination. As most protein ubiquitination sites tend to be exposed to the solvent, we calculated the solvent-accessible surface area (SASA) of the 10 lysine residues (K6, K13, K46, K63, K77, K82, K95, K97, K117, and K132) in the high-resolution X-ray crystal structure of PIN1 (PDB ID:1PIN). Lys117 emerged as the lysine residue with the highest solvent accessibility (Fig. 5C and Supporting Table S1), suggesting that K117 is a highly exposed residue and may therefore serve as the PIN1 ubiquitination site. Indeed, mutation of Lys117 to arginine (K117R) abolished mono-ubiquitination of PIN1 (Fig. 5D and Supporting Fig. S5C), and subsequently resulted in an increase of PIN1 half-life in vivo in cells (Fig. 5E and Supporting Fig. S5D). Although we cannot completely rule out by site-directed mutagenesis that other lysine residues within PIN1 could be targets for mono-ubiquitination, mutating Lys46, which has the second highest solvent accessibility, did not abrogate the ubiquitination of PIN1 (Supporting Fig. S5C). These results indicate that, most likely, Lys117 residue on PIN1 is the major site subjected to mono-ubiquitination needed for its degradation.

To gain insights into the structural basis of Ser115 phosphorylation-mediated inhibition of PIN1 mono-ubiquitination, we performed atomistic molecular dynamics (MD) simulations in explicit solvent of unphosphorylated Ser115 (S115) and phosphorylated Ser115 (p-S115) PIN1 (Supporting Fig. S5E; see also Supporting Methods). Five independent MD simulations of 100 ns were carried out for each Ser115 state, starting from the crystallographic coordinates of PIN1 resolved at 1.35 Å. Comparison of the atomic RMS deviations (RMSDs) from the starting structure revealed that, although both unphosphorylated and phosphorylated PIN1 displayed low deviations with respect to the X-ray structure, phosphorylated PIN1 showed higher deviations compared with the unphosphorylated PIN1 (Supporting Fig. S5F,G). Consistent with the RMSD results, analyses of the atomic RMS fluctuations revealed a significant increase in the flexibility of residues 115-117 upon phosphorylation of Ser115 (Supporting Fig. S5H). Taken together, our simulations suggest that phosphorylation at Ser115 induces significant local changes in the dynamics of PIN1. Interestingly, analyses of the SASA value for the 10 lysine residues of PIN1 throughout the MD simulations revealed a significant decrease in the solvent accessibility of Lys117 upon phosphorylation of Ser115 (Supporting Fig. S5I). All other lysine residues displayed no significant differences in the average SOLASA values between the unphosphorylated and phosphorylated PIN1 systems (Fig. 5F). Representative snapshots from one of the...
FIG. 5. JNK-mediated PIN1 Ser115 phosphorylation prevents its mono-ubiquitination at Lys117. Results shown are representative of at least three independent experiments. (A) Analysis of PIN1 WT and PIN1 mutant proteins stability by pulse-chase experiments. CCLP1 cells overexpressing FLAG-tagged PIN1-WT or PIN1 mutants (S114A, S115A, and S138A) were treated with CHX for the indicated times, harvested, and analyzed by WBs as indicated. Quantification of FLAG-PIN1 levels relative to tubulin is shown on the right panel. (B) In vivo ubiquitination assays showing the level of mono-ubiquitination of PIN1-WT and PIN1-S115A mutant proteins in CCLP1 cells stably co-expressing His-HA-ubiquitin with FLAG-PIN1-WT or FLAG-PIN1-S115A, in the presence of MG132. Ubiquitinated proteins were pulled down with Ni-NTA beads and analyzed by WB using anti-FLAG antibody. (C) Ribbon representation of PIN1 color-coded by domain (gray, WW domain; blue, PPIase domain). The 10 lysine residues of the enzyme are shown with ball-and-sticks (green C, blue N, and white H atoms), and values in parentheses indicate the relative solvent accessibility of their side-chain atoms (RSA, %), as calculated from a high-resolution crystal structure of PIN1 (PDB ID: 1PIN) using NACCESS. Also shown with orange C atoms are S115, C113, and the catalytic site histidine residues H59 and H157 (O atoms are shown in red and S in yellow). (D) In vivo ubiquitination assay in SP600125-treated CCLP1 cells stably co-expressing His-HA-ubiquitin with FLAG-PIN1-WT or FLAG-PIN1-K117R. Left: Ubiquitinated proteins were pulled down with Ni-NTA beads and analyzed by WBs using anti-FLAG antibody. Right: IP with anti-FLAG antibody followed by WBs with anti-ubiquitin antibody. (E) Analysis of PIN1-WT and PIN1-K117R proteins stability by pulse-chase experiments. Following treatment with SP600125, CCLP1 cells overexpressing FLAG-PIN1-WT or FLAG-PIN1-K117R mutant were treated with CHX for the indicated times, harvested, and analyzed by WB as indicated. Quantification of FLAG-PIN1 levels relative to tubulin is shown on the right panel. (F) Left: Plot of the mean SASA for each lysine residue of PIN1 (side-chain atoms only), calculated from (n = 5) independent 100-ns MD simulations of the enzyme in the unphosphorylated (S115) or phosphorylated (p-S115) state of Ser115. Data in bar graph are presented as mean ± SEM; circles represent individual data points. P values (y-axis) for each lysine of PIN1. Dotted grid lines are shown at x = 0 (no difference) and y = −log_{10}(0.05). K117 is the only lysine showing a significant difference. Abbreviation: Ub, ubiquitin.

The prolific role of PIN1 in cancer has triggered extensive efforts to design small molecule inhibitors targeting PIN1 function. (19-24,36) One such potent inhibitor of PIN1 is ATRA, which binds to PIN1 and induces its degradation. (27,36) As the JNK-PIN1 regulatory axis sustains ICC cell proliferation, we explored whether ATRA-induced PIN1 degradation could be used as a therapeutic strategy in cholangiocarcinoma. First, we treated ICC cells with increasing concentrations of ATRA and observed that ATRA treatment resulted in a dose-dependent decrease in the growth rate of ICC cells; however, ATRA had no effect on nontumoral H69 cholangiocytes (Fig. 7A).
As expected, the decrease in the cell growth rate was associated with a dose-dependent decrease in PIN1 protein levels (Fig. 7B), confirming that ATRA prevents PIN1 accumulation in ICC cells. Notably, ATRA treatment did not affect the phosphorylation/activity levels of JNK (Fig. 7B). A dose-dependent growth inhibitory effect of ATRA was also observed in ICC cells ectopically expressing PIN1 (Fig. 7C).

Next, we subcutaneously injected CCLP1 cells into NOD/SCID immunodeficient mice, and 2 weeks later we implanted either ATRA-releasing pellets or placebo pellets into the flanks of mice to assess the effects of ATRA on the ability of ICC cells to form tumors in vivo (Supporting Fig. S6A). After a median tumor growth period of 26 days, smaller tumors developed in ATRA-treated group compared with those in placebo-treated mice, as revealed by measuring tumor mass and tumor weight (Fig. 7D-F and Supporting Fig. S6B). WB analyses showed that PIN1 levels markedly decreased in the ATRA-treated tumors compared with those in placebo-treated tumors (Supporting Fig. S6C). Notably, expression levels of PIN1 did not correlate with those of p-JNK in tumors from ATRA-treated mice (Supporting Fig. S6C; see also Fig. 7B), suggesting a potential disruption of JNK-PIN1 regulatory axis by ATRA. These results suggest that ATRA-induced PIN1 degradation may have therapeutic potential against...
cholangiocarcinoma growth. Finally, we examined the biological importance of JNK-mediated PIN1 Ser115 phosphorylation in the response of ICC cells to ATRA. Compared with PIN1-depleted ICC cells reconstituted with rPIN1 WT, PIN1-depleted ICC cells reconstituted with rPIN1 S115A mutant were much less sensitive to ATRA-induced growth inhibition (Fig. 7G), implying that PIN1 Ser115 phosphorylation is crucial for the susceptibility of ICC cells toward ATRA.

Discussion

Activation of the JNK signaling pathway in cholangiocytes is a key event in cholangiocarcinogenesis and a promising target in ICC therapy. However, due to its multifunctional role in liver homeostasis, the development of selective therapies that target JNK directly are unlikely to result in clinically translatable options. Therefore, understanding the mechanism through which JNK activation promotes ICC growth and the identification of downstream effectors as druggable targets are critical steps for expanding the therapeutic management of ICC. Here we uncover a mechanistic link between JNK activity and ICC cell proliferation through PIN1 protein stabilization and demonstrate the potential application of the PIN1 inhibitor ATRA for ICC therapy.

Elevated levels of PIN1 were found in ICC cell lines as well as ICC tissues, and positively correlated with the phosphorylation/activity levels of JNK proteins. Intriguingly, the positive association between JNK activity and PIN1 levels appears to be specific to ICC cells, as it was not observed in nontumoral human biliary epithelial cells, in which JNK kinase activities are not constitutively up-regulated. While blocking JNK activity led to a significant decrease in PIN1 protein levels, ectopic expression of a constitutively active form of JNK1 (JNK1CA) led to an increase in endogenous PIN1 protein levels. Thus, PIN1 functions downstream of the JNK pathway, consistent with the established role of PIN1 in RAS signaling.

PIN1 was first identified as a key regulator of cell division and later shown to promote tumorigenesis and tumor progression by inactivating proliferation-restraining factors or activating proliferation-promoting factors. Consistent with the latter, we found that PIN1 is essential for proliferation of both cultured and xenografted ICC cells and functionally mimics JNK activation, thus reflecting the regulatory role of JNK activation on PIN1.

What then is the mechanism by which JNK activity regulates PIN1 expression? Activated JNK proteins regulate a variety of cellular processes, including proliferation, by acting on a number of nuclear and nonnuclear proteins at either transcriptional or post-translational levels. We found that JNK activity regulates the intracellular PIN1 levels by stabilizing PIN1 through its phosphorylation, thus preventing PIN1 mono-ubiquitination and proteosomal
degradation. This is demonstrated by showing that the newly synthesized endogenous PIN1 displayed a shortened half-life in JNK-depleted or SP600125-treated ICC cells, and the decreased intracellular protein levels of PIN1 were reversed by the addition of the proteasome inhibitor MG132. In JNK-depleted ICC cells, the decrease in PIN1 levels was associated with the appearance of a mono-ubiquitinated form of PIN1, implying that JNK proteins inhibit the mono-ubiquitination of endogenous PIN1. Furthermore, JNK kinase activity is strictly required for such inhibition as overexpression of the constitutively active form of JNK1, but not its nonactive form, inhibited PIN1 mono-ubiquitination. Thus, in accordance with previous works showing that protein stability of PIN1 is regulated through the ubiquitin-proteasome system and that small proteins are more likely to be mono-ubiquitinated rather than polyubiquitinated for degradation, constitutive JNK activation prevents PIN1 mono-ubiquitination-induced proteasomal degradation, resulting in the stabilization and elevated levels of PIN1. In line with our finding that JNK activity is required for preventing PIN1 mono-ubiquitination, we show that JNK proteins directly interact with and phosphorylate PIN1 at Ser115, thus pinpointing PIN1 as a direct downstream target of JNK signaling. Moreover, we show that the reconstituted expression of non-phosphorylatable PIN1 S115A mutant, which was resistant to JNK-mediated suppression of PIN1 mono-ubiquitination, failed to revert impaired ICC cell growth. Therefore, the stabilization of PIN1 upon phosphorylation at Ser115 by active JNK represents a causal link between JNK activation and high PIN1 levels, and defines the JNK-PIN1 axis as essential for cholangiocarcinoma proliferation.

Given that PIN1 is aberrantly expressed at high levels in various types of tumor, including HCC, B-cell lymphoma, brain and lung cancer, in which constitutive JNK activation is commonly observed, we speculate that the JNK-mediated stabilization of PIN1 may similarly contribute to the high expression of PIN1 in tumors of diverse tissue origin. Notably, many downstream effectors of the JNK pathway, such as c-Jun and cyclin D1, which promote cancer cell proliferation, are reported to be also regulated by PIN1. Interestingly, we found that the reconstituted expression of PIN1(S115A) mutant but not that of rPIN1 WT failed to revert the levels/activities of key cell proliferation regulators in ICC cells. Thus, it is reasonable to hypothesize that JNK-mediated PIN1 Ser115 phosphorylation may significantly contribute to the pro-proliferative function of activated JNK in many human cancers.

Targeting downstream effectors in JNK signaling is a promising approach for inhibition of tumor proliferation in JNK-dependent tumors. Our results point to PIN1 as a key downstream effector of the JNK pathway and show that the PIN1 inhibitor ATRA effectively impaired ICC cell growth both in vitro and xenograft experiments, with a corresponding decrease in PIN1 levels but not in JNK phosphorylation/activity. Although we cannot rule out that other mechanisms of action of ATRA could also be responsible for its growth inhibitory effect in ICC cells, ATRA treatment in ICC cells phenocopies the effects of PIN1 knockdown. Thus, one would expect that ATRA may interfere with the JNK-PIN1 regulatory axis and block its oncogenic function in ICC, while leaving JNK activation unaffected.

The obvious question that remains to be addressed is how JNK-mediated Ser115 phosphorylation inhibits PIN1 mono-ubiquitination. In agreement with the notion that protein ubiquitination occurs primarily on highly solvent-exposed lysine residues, we show that the Lys117 of PIN1 is the mono-ubiquitination site targeted for proteasomal degradation. Molecular dynamics simulations suggest that Lys117 displays a decreased solvent accessibility following phosphorylation at Ser115. Therefore, it is likely that JNK-mediated Ser115 phosphorylation may shield Lys117 from intermolecular interactions with components of the ubiquitination machinery by decreasing its surface exposure. Future investigations are warranted to address this question.

Our findings provide insights into the mechanisms by which constitutive JNK activation promotes cholangiocarcinoma growth and identify PIN1 as a direct downstream target of JNK, revealing an unexpected regulatory axis that sustains elevated PIN1 intracellular levels required for cell proliferation (Fig. 7H). We propose that targeting PIN1 using ATRA could be a potential therapeutic strategy for ICC. Rapid application of this strategy would be possible, as ATRA is a Food and Drug Administration-approved drug to treat APL and is currently being clinically trialed for treatment of other solid cancers (ClinicalTrials.gov: NCT04113863).
Acknowledgment: The authors thank Ulf Klein (University of Leeds) for the insightful comments to the manuscript; Michael B. Yaffe (MIT Center for Precision Cancer Medicine) for the GST-PIN1 plasmid; J. Zhang (Duke University) for the JNK1CA and JNK2CA; G. Franzoso (Imperial College London) for the c-Jun and shRNA lentiviral vectors; D. Trono (Ecole Polytechnique Federale de Lausanne, Switzerland) for the pWPI lentiviral vector; and D. Guardavaccaro (University of Verona) for the pWC7-His-Myc-Ubiquitin-WT, pCMV-His-HA-Ubiquitin-WT, and pWC7-His-Myc-Ubiquitin K0. They also thank L. Jary, D. Evans, and J. Bilton (University of Leeds) for the technical assistance.

Author Contributions: A.L., P.M.C., N.C.L., M.A.C., C.B., and S.P. performed most of the experiments. R.F., G.G., and M.L. helped with animal studies and data analyses. M.A.B.-O. performed quantitative PCR. S.S.G. and G.A. provided essential reagents and helped with data analyses. C.D’S. performed mass spectrometry analyses. A.P. performed the computational modeling and interpretation. R.M.T. and W.-K.S. helped with data analyses and interpretation. C.B. and S.P. are both senior and lead authors, conceived the idea, chiefly carried out data analysis and interpretation, coordinated and supervised the study, obtained research funding, and wrote the manuscript, which was commented by all the authors.

REFERENCES


Author names in bold designate shared co-first authorship.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31983/suppinfo.